{"product_id":"coherus-pestle-analysis","title":"Coherus Biosciences PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the complex external forces shaping Coherus Biosciences's trajectory with our comprehensive PESTLE analysis. Understand how political, economic, social, technological, legal, and environmental factors are creating both opportunities and challenges for the company. Gain a strategic advantage by leveraging these expert insights to inform your investment decisions or business planning. Download the full PESTLE analysis now and unlock a deeper understanding of Coherus Biosciences's market landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment healthcare policies are a significant driver for Coherus BioSciences. Initiatives aimed at promoting biosimilar adoption, such as favorable reimbursement rates and streamlined approval pathways, directly benefit companies like Coherus. For instance, the Inflation Reduction Act of 2022, while primarily focused on drug price negotiation, also signals a broader political intent to manage healthcare costs, which indirectly supports the market for more affordable biosimilars.\u003c\/p\u003e\n\u003cp\u003eValue-based care models, increasingly favored by policymakers, also play a crucial role. These models incentivize providers to focus on patient outcomes and cost-effectiveness, creating a fertile ground for biosimilars that offer comparable efficacy at a lower price point. Coherus's focus on developing and commercializing biosimilars for high-value biologics aligns well with this policy trend, potentially accelerating their market penetration and uptake.\u003c\/p\u003e\n\u003cp\u003eConversely, restrictive policies or a lack of political will to support biosimilar competition could pose challenges. Delays in regulatory review, inadequate reimbursement, or policies that favor originator biologics can create significant barriers to market entry and growth for Coherus. The political landscape's stance on healthcare affordability and innovation will continue to shape the opportunities and hurdles Coherus faces in the coming years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ongoing debate and implementation of drug pricing regulations, especially in key markets like the United States, directly impact Coherus Biosciences' revenue. Policies designed to curb pharmaceutical costs can boost demand for more affordable biosimilars, but they also create pressure on how Coherus prices its products. For instance, the Inflation Reduction Act of 2022, which allows Medicare to negotiate prices for certain high-cost drugs, could influence the market landscape for biologics and biosimilars in the coming years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Approval Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe clarity and efficiency of biosimilar approval pathways, like those managed by the FDA and EMA, directly impact Coherus Biosciences' ability to bring its products to market. Streamlined processes are crucial for reducing development timelines and costs, allowing for quicker market entry for biosimilars such as Coherus's Udenyca. For instance, the FDA's pathway, established by the Biologics Price Competition and Innovation Act (BPCIA), has been evolving, with the agency aiming to enhance predictability for developers.\u003c\/p\u003e\n\u003cp\u003eChanges or ambiguities in these regulatory frameworks present significant hurdles for Coherus. The FDA's continued efforts to refine its biosimilar review process, including guidance on interchangeability, aim to foster greater competition. As of early 2024, the agency has approved over 40 biosimilars, demonstrating an ongoing commitment to facilitating market access, though specific pathway adjustments can still introduce uncertainty for pipeline planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational trade agreements significantly shape Coherus Biosciences' global strategy, particularly concerning its biosimilar products. These agreements dictate market access, pricing, and the enforceability of intellectual property (IP) rights, which are crucial for biosimilar manufacturers. For instance, the United States-Mexico-Canada Agreement (USMCA), which replaced NAFTA, includes provisions on intellectual property that could influence how Coherus navigates these markets.\u003c\/p\u003e\n\u003cp\u003eTariffs and trade disputes can directly impact Coherus's supply chain and profitability. A notable example is the ongoing trade friction between the United States and China, which has seen fluctuating tariff rates on various goods. Such disruptions can increase the cost of raw materials or finished products, affecting the competitive pricing of biosimilars. In 2023, global trade growth was estimated to be around 0.9%, a slowdown that highlights the sensitivity of international commerce to political factors.\u003c\/p\u003e\n\u003cp\u003eExpanding into new international markets necessitates a deep understanding of diverse political landscapes and existing trade relations. Coherus must consider the regulatory frameworks and patent protection laws in each target country. For example, the European Union's unified market and its specific regulations for biosimilars offer a different pathway compared to navigating individual national markets in Asia or Latin America. The World Trade Organization (WTO) plays a role in setting global trade rules, but regional agreements often take precedence in day-to-day operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntellectual Property Protection:\u003c\/strong\u003e Global trade pacts, like those overseen by the WTO, define the strength and duration of patent protections, directly impacting Coherus's ability to launch and compete with biosimilars.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access and Tariffs:\u003c\/strong\u003e Trade agreements can reduce or eliminate tariffs, facilitating easier market entry for Coherus's products, while trade disputes can impose barriers and increase costs. For example, the US Chamber of Commerce reported that tariffs can add significant costs to imported goods used in manufacturing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Harmonization:\u003c\/strong\u003e International agreements can promote regulatory harmonization, simplifying the approval process for biosimilars across different countries, though significant variations still exist.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeopolitical Stability:\u003c\/strong\u003e The stability of trade relations and the absence of major geopolitical conflicts are essential for Coherus to maintain stable supply chains and predictable market conditions for its international sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Stability and Healthcare Budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical stability in Coherus's key markets, particularly the United States and Europe, is crucial. Changes in government or policy can directly affect healthcare spending and reimbursement policies for biosimilars, impacting Coherus's revenue streams. For instance, shifts in US political administrations can alter the approach to drug pricing and biosimilar adoption incentives.\u003c\/p\u003e\n\u003cp\u003eThe allocation of national healthcare budgets significantly influences the purchasing power for pharmaceuticals, including biosimilars. Economic downturns or a reallocation of government priorities can lead to budget constraints within healthcare systems. This could result in reduced uptake or downward pressure on the pricing of biosimilars, directly affecting Coherus's market penetration and profitability.\u003c\/p\u003e\n\u003cp\u003eCoherus must closely monitor these macro-political trends and their potential impact on its business. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolitical Stability:\u003c\/strong\u003e Continued stability in the US and EU markets supports predictable healthcare policies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealthcare Budget Allocation:\u003c\/strong\u003e Government decisions on healthcare spending directly influence the market size for biosimilars.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReimbursement Policies:\u003c\/strong\u003e Favorable reimbursement landscapes are critical for biosimilar adoption and pricing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Environment:\u003c\/strong\u003e Evolving regulatory frameworks for biosimilars can create both opportunities and challenges.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Policy and Biosimilar Market Evolution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment healthcare policies are a significant driver for Coherus BioSciences, with initiatives promoting biosimilar adoption directly benefiting the company. The Inflation Reduction Act of 2022, while focused on drug price negotiation, signals a broader political intent to manage healthcare costs, indirectly supporting the market for more affordable biosimilars.\u003c\/p\u003e\n\u003cp\u003eValue-based care models, increasingly favored by policymakers, incentivize providers to focus on patient outcomes and cost-effectiveness, creating a fertile ground for biosimilars. Coherus's focus on developing biosimilars for high-value biologics aligns well with this trend, potentially accelerating market penetration.\u003c\/p\u003e\n\u003cp\u003eRestrictive policies or a lack of political will to support biosimilar competition can pose challenges, such as delays in regulatory review or inadequate reimbursement. The political landscape's stance on healthcare affordability and innovation will continue to shape Coherus's opportunities and hurdles.\u003c\/p\u003e\n\u003cp\u003eThe clarity and efficiency of biosimilar approval pathways, managed by agencies like the FDA, directly impact Coherus's ability to bring products to market. Streamlined processes reduce development timelines and costs, allowing for quicker market entry. As of early 2024, the FDA had approved over 40 biosimilars, demonstrating a commitment to market access.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis PESTLE analysis provides a comprehensive examination of the external macro-environmental factors influencing Coherus Biosciences, covering Political, Economic, Social, Technological, Environmental, and Legal dimensions.\u003c\/p\u003e\n\u003cp\u003eIt offers actionable insights for strategic planning by identifying key opportunities and threats within the biosciences sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear, actionable summary of Coherus Biosciences' PESTLE analysis, presented with a focus on identifying and mitigating external threats and capitalizing on opportunities, thereby acting as a critical pain point reliever for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Spending Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal healthcare spending is projected to reach $11.6 trillion by 2025, up from an estimated $10 trillion in 2023, according to Deloitte. This upward trend in healthcare expenditures, driven by aging populations and advancements in medical technology, directly influences the market size and growth potential for biosimilar manufacturers like Coherus Biosciences.\u003c\/p\u003e\n\u003cp\u003eThe increasing financial burden of healthcare costs is a significant economic driver for biosimilar adoption. In the United States, prescription drug spending alone reached $348 billion in 2022, highlighting the substantial costs that payers and patients face. This economic pressure creates a favorable environment for biosimilars, which offer substantial cost savings compared to their originator biologic counterparts, thereby expanding market opportunities for Coherus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effectiveness of Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe economic value proposition of biosimilars, offering significant cost savings compared to originator biologics, is a primary driver for their adoption.  For instance, biosimilars for adalimumab, like Coherus's Udenyca, have shown the potential to reduce annual treatment costs by hundreds of millions of dollars for healthcare systems. Payers and healthcare systems are increasingly focused on cost-efficiency without compromising quality, making this a crucial factor.\u003c\/p\u003e\n\u003cp\u003eCoherus's ability to clearly demonstrate the cost-effectiveness of its biosimilar products is key to market penetration.  Studies in 2024 and projections for 2025 indicate that biosimilar uptake can lead to substantial savings, with some analyses suggesting billions in potential savings across various therapeutic areas. This focus on economic value directly influences formulary placement and reimbursement decisions, impacting Coherus's commercial success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Interest Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation and interest rates significantly shape Coherus Biosciences' financial landscape. For instance, the US inflation rate hovered around 3.4% in April 2024, impacting the cost of raw materials and R\u0026amp;D.  The Federal Reserve's benchmark interest rate, maintained between 5.25% and 5.50% as of May 2024, directly affects the cost of capital for Coherus's expansion and new drug development initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive Landscape and Pricing Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe biosimilar market is fiercely competitive, with numerous players vying for market share against both biosimilar rivals and established originator biologics. This intense rivalry directly translates into significant pricing pressure, forcing companies like Coherus to carefully calibrate their pricing strategies to remain competitive while ensuring profitability.\u003c\/p\u003e\n\u003cp\u003eFor Coherus, this means navigating complex tender processes and rebate structures common in the pharmaceutical industry. Successfully gaining market share often requires aggressive pricing, which can impact gross margins. For instance, in the U.S. biosimilar market, pricing discounts on biosimilars compared to reference products can range significantly, impacting revenue per unit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntense Competition:\u003c\/strong\u003e The biosimilar market faces competition from multiple manufacturers and originator biologics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Pressure:\u003c\/strong\u003e Fierce competition leads to downward pressure on prices, affecting profit margins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Pricing:\u003c\/strong\u003e Coherus must balance market penetration with profitability through strategic pricing decisions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNavigating Rebates:\u003c\/strong\u003e The company must manage complex rebate programs and tender processes to secure market access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal economic growth directly impacts Coherus BioSciences by influencing healthcare spending and the adoption of biosimilars. A robust global economy generally translates to higher disposable incomes, allowing patients and healthcare systems to afford more advanced treatments. For instance, the International Monetary Fund (IMF) projected global growth to be 3.2% in 2024, a slight slowdown from 2023, which could moderate healthcare investment, but still indicates expansion.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns, conversely, can strain healthcare budgets, leading to increased price sensitivity and a greater demand for cost-effective alternatives like biosimilars. As of early 2025, many developed economies are navigating persistent inflation and higher interest rates, which could pressure healthcare providers to seek savings. This environment, however, could also accelerate biosimilar uptake as payers and providers look for ways to manage costs.\u003c\/p\u003e\n\u003cp\u003eThe accessibility of healthcare and government funding for health initiatives are also tied to the broader economic climate. In periods of strong growth, governments may allocate more resources to public health programs and drug reimbursements, benefiting companies like Coherus. Conversely, during economic contractions, such funding can be reduced, potentially impacting market access for new therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal economic growth forecast for 2024: 3.2% (IMF projection).\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on healthcare spending: Strong growth boosts disposable income and healthcare budgets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEconomic contractions: Can lead to budget constraints and increased demand for cost-saving biosimilars.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInflationary pressures: May influence payer decisions towards biosimilar adoption in 2024\/2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economy's Grip on Biosimilars: Costs, Competition, Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global economic landscape significantly influences Coherus Biosciences' operational environment.  Projected global growth of 3.2% for 2024, as per the IMF, suggests continued, albeit moderate, expansion in healthcare spending.  However, persistent inflation and higher interest rates in many developed economies during 2024 and early 2025 are creating budget pressures for healthcare providers, potentially accelerating the adoption of cost-saving biosimilars like those offered by Coherus.\u003c\/p\u003e\n\u003cp\u003eThe company's financial health is directly impacted by inflation and interest rates. With US inflation around 3.4% in April 2024 and the Federal Reserve's benchmark rate at 5.25%-5.50% as of May 2024, Coherus faces increased costs for raw materials and R\u0026amp;D, alongside a higher cost of capital for expansion and development.\u003c\/p\u003e\n\u003cp\u003eIntense competition within the biosimilar market, including from originator biologics, exerts significant pricing pressure. This necessitates strategic pricing by Coherus to balance market penetration with profitability, often involving navigating complex rebate structures and tender processes to secure market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEconomic Factor\u003c\/td\u003e\n\u003ctd\u003e2024\/2025 Data Point\u003c\/td\u003e\n\u003ctd\u003eImpact on Coherus Biosciences\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Economic Growth\u003c\/td\u003e\n\u003ctd\u003eIMF projection: 3.2% for 2024\u003c\/td\u003e\n\u003ctd\u003eModerates healthcare investment but still indicates expansion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation Rate (US)\u003c\/td\u003e\n\u003ctd\u003eApprox. 3.4% (April 2024)\u003c\/td\u003e\n\u003ctd\u003eIncreases costs for raw materials and R\u0026amp;D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal Funds Rate (US)\u003c\/td\u003e\n\u003ctd\u003e5.25%-5.50% (May 2024)\u003c\/td\u003e\n\u003ctd\u003eRaises the cost of capital for Coherus's initiatives.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Spending Trend\u003c\/td\u003e\n\u003ctd\u003eProjected to reach $11.6 trillion by 2025\u003c\/td\u003e\n\u003ctd\u003eIncreases market size and growth potential for biosimilars.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This comprehensive PESTLE analysis of Coherus Biosciences provides a detailed examination of the Political, Economic, Social, Technological, Legal, and Environmental factors impacting the company. You'll gain valuable insights into market dynamics and strategic considerations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55612018721145,"sku":"coherus-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/coherus-pestle-analysis.png?v=1754766797","url":"https:\/\/growthsharematrix.com\/products\/coherus-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}